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Abstract
Background: Acinar cell carcinoma (ACC) is a relatively rare pancreatic neoplasm with poorly defined prognosis.
This study aimed to investigate this rare pancreatic neoplasm through comparing patients with ACC to pancreatic
ductal cell adenocarcinoma (DCA).
Methods: Tianjin Medical University Cancer Institute and Hospital pathology database was reviewed from 1995 to
2015, and 19 patients with pathologically confirmed ACC were enrolled while 19 conventional DCA patients
assigned randomly as control. Retrospective review and follow-up were performed for each patient. Regression
methods were used to identify differences between ACC and DCA.
Results: In our study, most patients suffered from abdominal or back pain, and no lipase hypersecretion syndrome
was observed. For ACC, resected cases had better survival than those without resection, and earlier staging was
related to longer survival. Resection with postoperative adjuvant therapy had a better outcome than surgery alone.
Twelve cases developed recurrence. Compared to DCA, ACC had earlier staging and better survival. The
overall 1-, 2-, and 5-year survival rates for patients with ACC were 73.7, 26.3, and 5 %, respectively.
Conclusions: ACC carries a better prognosis than DCA and a similarly high recurrence rate, while surgical
resection proved the best first-line approach for it. A well-planned neoadjuvant or adjuvant chemoradiotherapy indeed
benefit the patients with ACC.
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Background
Acinar cell carcinoma (ACC) is a relatively rare pancre-
atic neoplasm with poorly defined prognosis [1, 2]. The
first case of ACC was reported by Berner in 1908 [3]. He
described a kind of syndrome that is characterized by
fever, polyarthritis, subcutaneous fat nodular necrosis,
and eosinophilia. Now it is known to be secondary to
lipase hypersecretion by the tumor and recognized as
lipase hypersecretion syndrome [1, 2, 4–6]. It is a kind
of huge, exophytic, well-circumscribed, and hypovascular
mass and favors a head of the pancreas distribution
topographically, but sometimes in any other part of
the pancreas.
The tumor is classically seen in older male, usually in
their sixth or seventh decade. Although the pancreas is
made up predominantly of acinar cells by 82 % in volume
[7], the ACC accounts for approximately 1 % of all
primary pancreatic neoplasm [8–10]. The reason is still
unclear, and some researchers speculated that acinar cells
may undergo a metaplasia into ductal cells when they met
with genetic instability [11–15]. According to reports in
the literature, the prognosis of ACC remains a contro-
versy, mixed with a poorer prognosis [9, 16] and others
showing a better prognosis compared to DCA [1, 2, 17].
In contrast, it is generally accepted that most patients with
ACC have high rates of recurrence [1, 2, 18]. Furthermore,
some estimated ACC to be more indolent, similar to the
neuroendocrine pancreatic tumors [1]. Past research
reported median survival for ACC ranging from 18 to
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33 months [1, 2, 16, 18, 19], with a 39-patient single-
institution case series demonstrating a 19-month median
survival [2]. In general, the preoperative diagnosis of ACC
is rarely achieved and the prognosis is poor, due to the
metastatic disease and a high recurrence rate [1, 2].
There have been a limited number of small case series
concentrating on the prognosis and clinical features of
ACC [1, 2, 6, 16, 18–22]. Thus, the objective of this
study is to present the experience of ACC to better
understand its clinical characteristics, pathology, treat-
ment, survival outcomes, and patterns of recurrence.
We also determined that there was a significant differ-
ence in the survival of ACC compared to DCA.
Methods
Patients
We performed a retrospective review of prospectively
collected surgical and pathological databases between
1995 and 2015 at Tianjin Medical University Cancer In-
stitute and Hospital for all cases of acinar cell carcinoma
of the pancreas, and 19 patients with pathologically con-
firmed ACC were enrolled, while 19 conventional DCAs
assigned randomly as control. For the patients within
the study, we collected their demographic information,
preoperative clinical symptoms, imaging results, opera-
tive and pathological findings, tumor size and staging,
postoperative complications, mortality, and survival. As
part of our study, all the patients had tissue specimens
from surgical resection or pathological results at our in-
stitution. The study was approved by the Institutional
Review Board (IRB) of Tianjin Medical University Cancer
Institute and Hospital. All patients provided written con-
sent for the storage of their information in the hospital
database and for the use of this information in our
research.
Follow-up and survival endpoints
Postoperative follow-up was performed through a hos-
pital visit, by telephone, or by mail every 3 months.
Follow-up was available for all 19 patients with a median
follow-up time of 22 months. The endpoint of the study
was overall survival (OS). OS was calculated as a period
of time from the date of diagnosis to the date of death of
any cause or the date of last follow-up.
TNM staging of ACC and DCC
According to the 7th edition of the AJCC (American
Joint Commission on Cancer) TNM staging system,
postoperative T staging was as follows: T0, no evidence
of primary; Tis, in situ; T1, limited to pancreas (≤2 cm);
T2, limited to pancreas (>2 cm); T3, extends beyond
pancreas, no involvement of CA or SMA; T4, involves
CA or SMA. Postoperative N staging was as follows: N0,
no nodal metastasis; N1, regional lymph node metastasis.
Postoperative M staging was as follows: M0, no distant
metastasis; M1, distant metastasis.
Statistical analysis
Clinicopathological features and survival were analyzed.
Mean and median survival were estimated using Kaplan-
Meier methods and compared through the log-rank test.
Potential prognostic factors were tested using the log-
rank test. Categorical variables were compared using the




From 1995 to 2016, 19 patients pathologically proven
ACC were identified in Tianjin Medical University Can-
cer Institute and Hospital from a retrospective review of
the pathology database, assigned to the case group. For
comparison to conventional ductal cell adenocarcinoma
(DCA), we assigned 19 matched cases to the control
group randomly during the same time (Table 1). The
mean and median ages of patients in our institution
were 54.2 and 54 years (range 39–77), respectively, with
84.2 % being male. Prevalent clinical symptoms were ab-
dominal pain or discomfort (n = 16), weight loss (n = 19),
back pain or discomfort (n = 14), pancreatic leakage (n =
10), bile leakage (n = 9), diabetes (n = 9), and nausea/
vomiting (n = 7). Tumor location was predominantly in
the head (n = 8) and tail (n = 9) and only a few in the
body (n = 2). Different from the conventional ductal cell
adenocarcinoma (DCA), no jaundice was found in pa-
tients with a head cancer, which was the classic presen-
tation [10]. Furthermore, the tumor marker CA19-9 was
commonly elevated in invasive DCA, and according
to the laboratory examination, there was no elevated
CA 19–9 with a median value of 21.70 U/L (range
4.6–28.1 U/L). Two patients (patient 4, 15) were
tested to have elevated serum lipase, however, without
classic clinical manifestations of lipase hypersecretion
syndrome. Of the case group (n = 19), features seen
on preoperative CT scan included a hypovascular-
hypodense mass (n = 18), exophytic tendency (n = 14),
well-circumscribed thickened border structure (n = 10),
and necrosis within the tumor (n = 7).
Therapy procedure
Among these 19 patients in the case group (Fig. 1), three
of them (patients 5, 14, and 17) were found extensive
tumor invasion (SMA or transverse colon), metastatic
disease (liver), or cancer cachexia during preoperative
evaluation. None of them received radical or palliative
resection. Two (patients 14 and 17) received chemother-
apy and one (patient 5) received nothing for economic
reasons. All the remaining 16 patients underwent
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Table 1 Patient characteristics
Patient Age Gender Stage and T Size (cm) Operation Survival (months) Recurrence Chemo/rad Alive/dead
1 58 Male IIAt3 5 Distal pancreatectomy 23 Local +/− Alive
2 54 Male IBt2 4.2 Pancreaticoduodenectomy 76 None +/− Alive
3 46 Male IIIt4 3.5 Distal pancreatectomy 11 Liver −/− Dead
4 41 Male IBt2 3.7 Distal pancreatectomy 54 Local +/− Alive
5 52 Female IVt4 5.7 None 5 Liver −/− Dead
6 55 Male IIIt4a 7.6 Gastrojejunostomy 13 Liver +/+ Dead
7 52 Male IBt2 9 Pancreaticoduodenectomy 19 Local +/− Alive
8 39 Male IIBt3 11.8 Pancreaticoduodenectomy 17 Local −/− Dead
9 47 Female IIBt2 6.3 Pancreaticoduodenectomy 21 None +/− Alive
10 49 Female IBt2 5.4 Distal pancreatectomy 34 None +/− Alive
11 54 Male IIBt3 6.5 Pancreaticoduodenectomyc 16 Local +/− Dead
12 48 Male IIAt3 2 Distal pancreatectomy 33 None +/− Alive
13 49 Male IIBt2 7.6 Distal pancreatectomy 21 None +/− Alive
14 71 Male IVt4 5.6 None 11 Distant +/− Dead
15 60 Male IIAt3b 5.4 Distal pancreatectomy 21 days None −/− Dead
16 56 Male IIBt3 3.5 Pancreaticoduodenectomy 18 None +/− Alive
17 68 Male IVt4 4.9 None 9 Local +/− Dead
18 77 Male IIBt3 5.7 Distal pancreatectomy 17 Local +/− Alive
19 54 Male IIAt3 2.8 Pancreaticoduodenectomy 27 Local +/− Alive
aSuperior mesenteric artery (SMA) and port vein (PV) were found invaded by the tumor in initial operation, so the patient received a palliative gastrojejunostomy
bPatient was found suffering from an infection of biliary tract after pancreaticoduodenectomy
cPatient was found to be locally advanced during the initial exploratory laparotomy, then received neoadjuvant chemotherapy, and on re-exploration was
found resectable
Fig. 1 Schematic of patient treatment. Among 19 patients, three of them received palliative therapy because of the advanced diseases. The
remaining 16 patients underwent exploratory laparotomy. Two of them were found unresectable, and the rest 14 patients received radical
resection with R0 margins, 6 pancreaticoduodenectomy, and 8 pancreatectomy
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exploratory laparotomy. During the initial operation, two
of them (patients 6 and 11) were found unresectable.
One (patient 11) with locally advanced tumor underwent
subsequent neoadjuvant chemotherapy (gemcitabine)
and was re-evaluated by CT scan, demonstrating a per-
mission for surgical resection. The patient was resected
(pancreaticoduodenectomy) at re-exploration with R1
margins. Another (patient 6) with SMA and PV invaded
received palliative gastrojejunostomy with R2 margins
and chemoradiotherapy postoperatively. The rest 14
patients underwent radical resection with R0 margins
initially, with six patients undergoing pancreaticoduode-
nectomy and eight patients having a distal pancreatec-
tomy with a concurrent splenectomy. Median survival
was 18 month (range 1–76). Median resected tumor size
was 5.40 cm (range 2.00–11.80). Among these resected
cases, one of them (patient 15) was found suffering from
an infection of biliary tract after pancreaticoduodenect-
omy and died 21 days postoperatively of septic shock.
According to the 7th edition of the AJCC (American
Joint Commission on Cancer) TNM staging system, the
case group tumor pathological staging were stage I (n = 4),
stage II (n = 10), stage III (n = 2), and stage IV (n = 3). Of
the patients who underwent exploratory laparotomy
(n = 16), all of them had postoperative pathology con-
firming a diagnosis of ACC. Of the remaining three
patients, each of them was diagnosed by cytopathology
from endoscopic retrograde cholangiopancreatography
(ERCP) brushing. To a certain extent, further diagnostic
immunohistochemical stains for antichymotrypsin and
antitryptase (n = 10) also made great contributions to
pathologic diagnosis of ACC. The lipase examination was
done in all 19 patients, revealing positive results in
patients 2, 4, 6, 14, and 17, respectively.
Follow-up
Postoperative follow-up was available for all cases. Median
survival time in the case group (n = 19) was 18 months,
with actuarial survival at 1, 2, and 5 years estimated to be
73.7, 26.3, and 5 %, respectively (Table 2). Twelve cases
(63.1 %) developed recurrence (8 local, 3 liver, 1 distant),
demonstrated on postoperative follow-up CT scans
(Table 1). Overall stage-specific (Fig. 2a) survival were
stage I 21.0 % (mean survival 45.75 months), stage II
52.6 % (mean survival 19.4 months), stage III 10.5 %
(mean survival 12.0 months), and stage IV 15.8 % (mean
survival 8.33 months). Earlier staging was associated with
better 5-year survival (P < 0.05). For ACC, the resected
cases had a significantly better survival than those without
resection (median survival 19 vs. 9 months, P < 0.0001
Fig. 2b), while earlier T classification related to a longer
survival time (P < 0.05 Fig. 2c). In our study, resected cases
with postoperative adjuvant therapy had a better outcome
than those received surgery alone (P = 0.006 Fig. 2d).
Analysis of prognosis
According to multivariable analysis (Table 3), the case
group (n = 19) was predominantly male, larger tumors,
less nodal metastases, and more frequently located in tail
than in the head of the pancreas. Potential prognostic
factors for long-term survival are earlier T classification
and negative nodal metastases (Table 4).
Comparison to DCA
For comparison to DCA, we assigned 19 matched cases
to the control group randomly during the same time
(Table 2). Compared with the control group (n = 19), the
case group (n = 19) was younger (median 54 vs. 65 years,
P = 0.001) and more likely to be male (84.2 % vs. 53.3 %,
Table 2 Patient characteristics compared with DCA
Acinar cell carcinoma Ductal cell carcinoma P value
Number of patients 19 19
Gender Male 16 10 0.036
Female 3 9
Median age (year) 54 (39–77) 65 (35–86) 0.001
Median survival (month) 18 (11–27) 4 (3–12) <0.0001
Median tumor size (cm) 5.4 (2–11.8) 3.1 (2.1–6.4) <0.001
Stage S I 4 1 0.021
S II 10 4
S III 2 2
S IV 3 12
Location within pancreas Head 8 14 0.013
Body 2 4
Tail 9 1
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P = 0.027). Moreover, the case group had larger tumors
(5.4 vs. 3.1 cm, P < 0.001), earlier staging (stage I + II
73.6 % vs. 26.7 %, P < 0.05), and longer survival time (18
vs. 4 months, P < 0.0001 Fig. 3). For the resected ones
(Table 5), the case group (n = 16) had a larger male ten-
dency than the control group (n = 14), and larger tumors
(5.40 vs. 3.75 cm, P < 0.001). Based on the 7th edition of
the AJCC criteria, ACC had earlier T classification (P =
0.023) and less nodal metastases (P = 0.001) than DCA.
Discussion
Acinar cell carcinoma is a rare malignancy of the exo-
crine pancreas, and comprehensive retrospective institu-
tional cases series are not easily available to make
accurate conclusions of outcomes and clinical character-
istics of ACC. This study, a total of 19 patients of ACC,
aims to make contributions to the limited understanding
about these lesions. By presenting experience from our
institution, we sought to better define the clinical char-
acteristics of ACC.
In our study, patients with ACC were predominantly
males with median age of 54 years (range 39–77),
Fig. 2 The Kaplan-Meier actuarial survival curves for ACC patients. a Overall stage-specific survival were stage I 21.0 % (mean survival 45.75 months),
stage II 52.6 % (mean survival 19.4 months), stage III 10.5 % (mean survival 12.0 months), and stage IV 15.8 % (mean survival 8.33 months). b The
resected cases had a significantly better survival than those without resection (median survival 19 vs. 9 months, P < 0.0001). c Among resected cases,
earlier T classification was associated with a longer survival time (P < 0.05). d Resection followed by postoperative adjuvant therapy had a
better outcome than surgery alone (P = 0.006)
Table 3 Factors associated with ACC compared to DCA
Odds ratio (95 % CI) P value
Gender Female 1.0 (referent)
Male 4.667 (1.121–19.434) 0.034
Tumor size <2.0 cm 1.0 (referent)
2.1–4.0 cm 0.233 (0.063–0.870) 0.030
>4.0 cm 11.200 (2.882–43.531) <0.0001
Nodal metastases N1 1.0 (referent)
N0 12.444 (2.891–53.562) 0.001
Location Head 1.0 (referent)
Body 1.580 (1.022–2.604) 0.004
Tail 5.850 (1.464–23.377) 0.012
Odds ratios >1.0 indicate a higher likelihood of ACC compared to DCA. Factors
that were not significant in the model were age, tumor grade, and
distant metastases
Table 4 Potential prognostic factors for long-term survival after
the resection of ACC
Hazard ratio (95 % CI) P value
Nodal metastases 20.370 (2.242–185.104) 0.007
T classification 16.308 (2.078–127.976) 0.008
Hazard ratios >1.0 indicate a higher risk of death within 5 years. Potential
prognostic factors for long-term survival are earlier T classification and negative
nodal metastases. Factors not significant in the model include resection margins
and size of the tumor
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younger than DCA. Holen et al. [2] and Klimstra et al.
[1] also suggested an overall younger age of ACC than
pancreatic adenocarcinoma and similar male/female ra-
tio, 31:8 and 24:4, respectively. Meanwhile, ACC had lar-
ger tumors compared to DCA (5.4 vs. 3.1 cm, P < 0.001).
Prevalent clinical symptoms in our study were abdom-
inal pain or discomfort (n = 16), weight loss (n = 19),
back pain or discomfort (n = 14), pancreatic leakage (n =
10), bile leakage (n = 9), diabetes (n = 9), and nausea/
vomiting (n = 7), similar with the distribution commonly
reported [23]. The classic presentation of painless ob-
structive jaundice did not occur in our study. Lipase hy-
persecretion syndrome is recognized to be secondary to
lipase hypersecretion by the tumor, which is relatively
specific for ACC [1, 2, 4–6]. Nevertheless, none of our
patients presented with this syndrome confirmed the
rarity reported by current literature [1, 2, 19].
During preoperative evaluation, features seen on CT
scan included hypovascular-hypodense mass (n = 18),
exophytic tendency (n = 14), well-circumscribed thick-
ened border structure (n = 10), and necrosis within the
tumor (n = 7). Consistent with our study, Tatli et al. re-
ported ACC as an exophytic, well-circumscribed, hypo-
vascular mass on CT scans, with necrosis when large
[24]. Moreover, Chiou et al. described that ACCs were
Fig. 3 The Kaplan-Meier actuarial survival curves for the entire cohort
by tumor type. The overall 1-, 2-, and 5-year survival rates for patients
with ACC were 73.7, 26.3, and 5 %, respectively (median 18 months),
whereas the overall survival rates for patients with DCA were 26.3, 2,
and 0 %, respectively (median, 4 months, P < 0001)
Table 5 Tumor characteristics and treatments of resected patients
ACC DCC P value
Number of patients 16 14
Gender Female 2 6 0.016
Male 14 8
Median tumor size (cm) 5.40 (2.00–11.80) 3.75 (2.1–6.4) <0.001




Nodal metastases N0 15 6 0.001
N1 1 8
Distant metastases M0 14 12 0.919
M1 2 2
Location within pancreas Head 7 10 0.004
Body 1 3
Tail 8 1
Margins R0 14 11 0.929
R1 1 2
R2 1 1
Surgical procedure Pancreaticoduodenectomy 7 9 0.008
Distal pancreatectomy 8 1
Gastrojejunostomy 1 1
Total pancreatectomy 0 3
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commonly hypodense mass on CT scans, accompanied
with occasional enhancing capsules, calcification, intra-
tumoral hemorrhage [19]. Although all of our patients
were evaluated through abdominal CT preoperatively,
none of them were definitively diagnosed through CT,
emphasizing the nonspecificity to the diagnosis of ACC.
Although preoperative pathological diagnosis of ACC
is rare, surgeon should keep ACC in mind when dealing
with such kind of patients. ACC is reported a malignant
tumor with poor outcomes [1, 2, 9, 16]; nevertheless,
our study demonstrated that ACC was associated with
better survival compared to DCA (median survival 18
vs. 4 months, P < 0.0001). Holen et al. [2] showed an
overall median survival of 19 months. Similar median
survival of 18.1 and 33 months were reported by Klimstra
et al. [1] and Akhil K. Seth et al. [18], respectively, far bet-
ter than the commonly reported median survival of DCA
(6 months) [25]. Overall, patients with ACC had a better
survival when compared to DCA [1, 2, 17]. However, we
observed a high recurrence rate of 56.3 % in resected ones
(9 of 16), including both local and distant metastases.
Holen et al. [2] similarly reported recurrence rate of 72 %.
Despite the well-circumscribed local confinement, ACC
remains aggressive in nature, like other invasive pancreatic
cancers, and is often a systemic disease with high recur-
rence rates [2]. Potential prognostic factors for long-term
survival are earlier T classification and negative nodal
metastases. Factors not significant in the model include
resection margins and the size of the tumor.
Surgical resection remains the best first-line approach
for ACC if lesion resection is possible. Holen et al. [2]
reported a median survival of 36 months for resected
ones, opposed to 14 months survival for those without
any resection. Consistently, in our study, the resected pa-
tients had significantly better survival than the unresected
ones (median 19 vs. 9 months, P < 0.0001). Therefore, sur-
gical resection indeed makes a huge contribution to long-
term survival in patients with ACC. Unfortunately, one of
them (patient 15) was found suffering from infection of bile
duct, as a postoperative complication, and died 21 days
postoperatively of septic shock. In consequence, surgeon
cannot be too careful to treat patients undergoing such
kind of fetal operation, in case of deadly complications.
Whether ACC is sensitive to adjuvant therapy remains
a controversial issue. According to a multivariable ana-
lysis reported by C. Max Schmidt et al. [12], patients
with ACC had no better survival after adjuvant therapy.
In contrast, a recent case report by Akhil K.Seth et al.
[18], from Johns Hopkins, demonstrated that preoperative
neoadjuvant therapy effectively downstaged four patients,
using either gemcitabine, 5-fluorouracil, or adriamycin,
ultimately allowing them as candidates again for surgical
resection. Meanwhile, a multi-institutional series from J.
M. Matos et al. [23] also contained patients downstaged
by neoadjuvant therapy [23]. Our study also included a
case (patient 11) which was effectively downstaged by
neoadjuvant chemoradiotherapy. From our multivariate
analysis, it indicated that receiving chemotherapy was
associated with better OS (Table 2). These data, to some
extent, are certainly encouraging that some patients
appeared to benefit from this approach. Further study is
required about the role of adjuvant and neoadjuvant
therapy and whether they can improve survival of
these patients. Due to endoscopic ultrasound-guided
core biopsy and immunohistochemistry [26], the pre-
operative diagnosis of ACC is easier to achieve. Since ag-
gressive surgery proved the most beneficial approach,
patients with locally advanced or metastatic tumor should
undergo well-planned neoadjuvant therapy, attempting for
surgical resection.
Since such, the results above suggested that surgical
resection remains the best first-line approach for ACC if
lesion resection is possible due to its more favorable sur-
vival, and surgeon must be cautious with this aggressive
malignancy, and guided their decision-making when
faced with a potential ACC. Furthermore, to some ex-
tent, a well-planned neoadjuvant or adjuvant chemother-
apy indeed benefit the patients. Nevertheless, limitations
still exist during our research. Among these 19 ACC
cases, some were admitted into institution many years
ago, but detailed pathologic review was not available.
Meanwhile, the sample size is relatively small. Conse-
quently, further institutional and multi-institutional large
scale studies are still required for a more detailed ana-
lysis of clinical manifestation, pathology, and appropriate
treatment modalities of this rare malignant tumor.
Conclusions
ACC carries a better prognosis than the more common
DCA and a similarly high recurrence rate, while surgical
resection proved the best first-line approach for it.
Meanwhile, a well-planned neoadjuvant or adjuvant
chemotherapy indeed benefit the patients with ACC.
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